Clinical Trial

Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis

Study acronym: DRIVEALS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 7, 2025 (before its estimated April 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to understand the clinical variability in a population of ALS patients using multidimensional biomarkers. The main questions it aims to answer are: * Which set of biomarkers explain genotypic-phenotypic correlations in ALS? * Which set of biomarkers can be used to subdivide the ALS population in homogeneous subgroups? Participants will undergo: * neurological evaluation * neurophysiological evaluation * neuropsychological evaluation * whole exome sequencing * biomarker measurement in CSF and plasma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-15.
Trial Details
NCT Number NCT06318598
Lead Sponsor Istituto Auxologico Italiano
Collaborators: A.O.U. Città della Salute e della Scienza, Ospedale San Raffaele
Conditions Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Enrollment 200 participants
Start Date 2023-04-11
Primary Completion 2026-04-10 (estimated)
Study Completion 2026-04-10 (estimated)
Updated on ClinicalTrials.gov 2025-05-07